New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
08:15 EDTCVMCEL-SCI receives regulatory clearance to expand Phase III trial into Austria
CEL-SCI Corporation announced that it has received regulatory clearance from the Austrian Federal Office for Safety in Health Care to begin patient enrollment in the company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine. Austria is the 14th country to participate in CEL-SCI’s trial which is already active in numerous clinics around the world. CEL-SCI’s Phase III trial is assessing the use of the company’s Multikine immunotherapy as a first line treatment for patients diagnosed with advanced primary head and neck cancer, prior to standard of care, which involves surgery, chemotherapy, and/or radiation therapy. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. Further expansion of CEL-SCI’s Phase III head and neck cancer trial is underway with a goal to have a total of 880 patients enrolled through about 100 clinical centers through by the end of 2015. Over 200 patients are already enrolled in, and being treated with Multikine.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:17 EDTCVMCEL-SCI reports enrolling 25 patients in February for Multikine study
CEL-SCI announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its phase III head and neck cancer trial for its investigational immunotherapy Multikine -- Leukocyte Interleukin, Injection. A total of 377 patients have been enrolled in study in head and neck cancer as of February 28. “During the month of February we also received clearance in the Philippines, Malaysia and Belarus to begin patient enrollment in those countries. This is expected to result in an even higher number of patients being enrolled in the study in March,” stated CEL-SCI CEO Geert Kersten. The goal is to enroll a total of 880 patients through approximately 100 clinical centers in about 25 countries by the end of 2015.
March 2, 2015
08:46 EDTCVMCEL-SCI cleared to enroll patients in trial in Belarus
Subscribe for More Information
February 19, 2015
08:06 EDTCVMCEL-SCI says Malaysia approves patient enrollment for Phase 3 Multikine trial
CEL-SCI announced the Ministry of Health Malaysia has cleared the company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine -- Leukocyte Interleukin, Injection -- in Malaysia. Malaysia is the 20th country to approve CEL-SCI’s Phase III trial, which now has over 350 patients enrolled. “Our plan called for having the trial cleared and conducted in a total of 21 countries, the United States plus 20 other countries. We are almost there,” stated CEO Geert Kersten. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use